<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="235484">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006489</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAAFOA12428</org_study_id>
    <secondary_id>R01AA012428</secondary_id>
    <secondary_id>NIH grant R01-AA-012428</secondary_id>
    <nct_id>NCT00006489</nct_id>
  </id_info>
  <brief_title>Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone)</brief_title>
  <official_title>Naltrexone and Cognitive-Behavioral Therapy for Patients With Alcoholism and Post-Traumatic Stress Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate naltrexone and cognitive-behavioral therapy treatments for alcohol
      dependence and post-traumatic stress disorder (PTSD). Subjects will be randomly assigned a
      6-month treatment of either: 1) naltrexone alone, 2) naltrexone with PTSD psychosocial
      therapy, 3) a placebo with PTSD psychosocial therapy, or 4) placebo alone. An enhanced
      medication management intervention will accompany all treatment conditions. Follow-up
      assessments will be completed at 9 and 12 months after treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PTSD Symptom Scale - Interview</measure>
    <time_frame>9 and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drinking Time Line Follow-back</measure>
    <time_frame>9 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory</measure>
    <time_frame>9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penn Alcohol Cravings Scale</measure>
    <time_frame>9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Scale</measure>
    <time_frame>9 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Alcoholism</condition>
  <condition>Alcohol Dependence</condition>
  <condition>Post-Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naltrexone alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naltrexone with CBT for PTSD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo with CBT for PTSD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive-Behavioral Therapy</intervention_name>
    <description>Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>Daily dosing 100 mg for 24 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pill Placebo daily dosing 24 weeks</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets criteria for alcohol dependence and post-traumatic stress disorder.

          -  Heavy drinking in the past 30 days (an average of more than 12 alcohol drinks per
             week with at least 1 day of 4 or more drinks).

          -  Successfully complete medical detoxification.

          -  Exhibit clinically significant trauma-related symptoms.

          -  Live in a commutable distance to the University of Pennsylvania and agree to
             follow-up visits.

          -  Aged between 18 and 65 years old.

          -  Able to provide an informed consent.

          -  Speak and read English.

        Exclusion Criteria:

          -  Current diagnosis of any substance dependence other than alcohol, nicotine, or
             cannabis.

          -  Evidence of opiate use in the past 30 days.

          -  Significant risk of violence or history of serious violent behavior during the past
             year.

          -  Continued contact with an intimate partner if assault by the partner is the index
             trauma.

          -  Changes in dosage or medication for any SSRI treatment in the three months prior to
             entering the study.

          -  Unstable or serious medical illness.

          -  Current severe psychiatric symptom.

          -  Mental retardation or another pervasive developmental disorder.

          -  Use of an investigational medication in the past 30 days.

          -  Pregnant, nursing or not using reliable contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edna B. Foa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Anxiety, University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>July 3, 2012</lastchanged_date>
  <firstreceived_date>November 8, 2000</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcoholism</keyword>
  <keyword>Alcohol Dependence</keyword>
  <keyword>Post-Traumatic Stress Disorder</keyword>
  <keyword>Naltrexone</keyword>
  <keyword>Cognitive Behavior Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
